Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and Its Anti-tumour Effect in Adult Patients With CD44v6 Expressing Solid Tumours

NCT06639191 is registered in ClinicalTrials.gov with Karolinska University Hospital as lead sponsor.

NCT NCT06639191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06639191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and Its Anti-tumour Effect in Adult Patients With CD44v6 Expressing Solid Tumours
Lead sponsor
Karolinska University Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
January 28, 2026
Completion date
November 1, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer head and neck, cervix carcinoma, non-small cell lung cancer stage iv, poorly differentiated thyroid carcinoma, thyroid gland anaplastic carcinoma, vulvar cancer, stage iv